Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies. In 2009, ~16,000 of the ~40,000 Phase I, II and III trials listed on ClinicalTrials.gov were related to cancer (~40%). This large interest stems from the existence of high unmet need for improved treatments of multiple types of cancer and the substantial market success of targeted cancer therapies launched in the past decade.